Selpercatinib has 5 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Anakinra, Cyp3a Inducers, Mao Inhibitors. Patients taking Selpercatinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Moderate
- 5
Moderate (5)
- Selpercatinib + Anakinra— Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministrat…
- Selpercatinib + Cyp3a Inducers— Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministrat…
- Selpercatinib + Mao Inhibitors— Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministrat…
- Selpercatinib + P-Gp Or Bcrp Substrates— RETEVMO is a P-gp inhibitor; concomitant use increases substrate plasma concentrations. Avoid coadministration; if unavo…
- Selpercatinib + Short-Acting Antacids— Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministrat…